Characteristic |
All women |
Regression |
Persistence |
Progression |
Progression |
|
(N = 349) |
Normal (n = 301) |
LSIL (CIN1) (n = 23) |
CIN2 (n =
15) |
CIN3+ (n = 10) |
Age (mean±SD), y |
39.3±10.6 |
39.1±10.5 |
38.4±10.9 |
40.2±10.9 |
40.6±12.4 |
Age groups, n (%) |
|
|
|
|
|
21-24 years |
25 (7.2%) |
20 (6.6%) |
3 (13.0%) |
1 (6.7%) |
1
(10.0%) |
≥25 years |
324 (92.8%) |
281 (93.4%) |
20 (87.0%) |
14
(93.3%) |
9 (90.0%) |
Cytology, n (%) |
|
|
|
|
|
NILM |
213 (61.0%) |
192 (63.8%) |
11 (47.8%) |
5 (33.3%) |
5
(50.0%) |
ASC-US |
58 (16.6%) |
49 (16.3%) |
3 (13.0%) |
4 (26.7%) |
2a (20.0%) |
LSIL |
78 (22.3%) |
60 (19.9%) |
9 (39.1%) |
6 (40.0%) |
3
(30.0%) |
AHPV, n (%) |
|
|
|
|
|
AHPV-GT+ |
58 (16.6%) |
43 (14.3%) |
4 (17.4%) |
6 (40.0%) |
5
(50.0%) |
HPV 16+ |
37 (10.6%) |
27 (9.0%) |
2 (8.7%) |
4 (26.7%) |
4
(40.0%) |
HPV 18/45+ |
21 (6.0%) |
16 (5.3%) |
2 (8.7%) |
2 (13.3%) |
1a (10.0%) |
AHPV-GT– |
291 (83.4%) |
258 (85.7%) |
19 (82.6%) |
9 (60.0%) |
5 (50.0%) |